Anaplastic Astrocytoma – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Anaplastic Astrocytoma – Pipeline Review, H1 2017’, provides an overview of the Anaplastic Astrocytoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma

The report reviews pipeline therapeutics for Anaplastic Astrocytoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Anaplastic Astrocytoma therapeutics and enlists all their major and minor projects

The report assesses Anaplastic Astrocytoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Anaplastic Astrocytoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Anaplastic Astrocytoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Anaplastic Astrocytoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Advantagene Inc

Alfa Wassermann SpA

Amgen Inc

AngioChem Inc

Astellas Pharma Inc

Bayer AG

Boehringer Ingelheim GmbH

Burzynski Research Institute Inc

Cavion LLC

Celldex Therapeutics Inc

Merrimack Pharmaceuticals Inc

Millennium Pharmaceuticals Inc

Novartis AG

Orbus Therapeutics Inc

Pfizer Inc

Tocagen Inc

Tragara Pharmaceuticals Inc

TVAX Biomedical Inc

ZIOPHARM Oncology Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Anaplastic Astrocytoma - Overview 8

Anaplastic Astrocytoma - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 16

Anaplastic Astrocytoma - Therapeutics Assessment 17

Assessment by Target 17

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Anaplastic Astrocytoma - Companies Involved in Therapeutics Development 26

Advantagene Inc 26

Alfa Wassermann SpA 26

Amgen Inc 27

AngioChem Inc 27

Astellas Pharma Inc 28

Bayer AG 28

Boehringer Ingelheim GmbH 29

Burzynski Research Institute Inc 29

Cavion LLC 30

Celldex Therapeutics Inc 30

Merrimack Pharmaceuticals Inc 31

Millennium Pharmaceuticals Inc 31

Novartis AG 32

Orbus Therapeutics Inc 32

Pfizer Inc 33

Tocagen Inc 33

Tragara Pharmaceuticals Inc 34

TVAX Biomedical Inc 34

ZIOPHARM Oncology Inc 35

Anaplastic Astrocytoma - Drug Profiles 36

(A-10 + AS-21) - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

AdRTSIL-12 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

afatinib dimaleate - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

alisertib - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

BAY-1436032 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

bendamustine hydrochloride - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

CDX-1401 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Cellular Immunotherapy for Gliomas - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

Cellular Immunotherapy for Oncology - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

eflornithine hydrochloride - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

flucytosine + TBio-01 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

flucytosine ER + vocimagene amiretrorepvec - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

G-207 - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

GliAtak - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

irinotecan hydrochloride - Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

irinotecan hydrochloride + TBio-02 - Drug Profile 105

Product Description 105

Mechanism Of Action 105

R&D Progress 105

M-032 - Drug Profile 107

Product Description 107

Mechanism Of Action 107

R&D Progress 107

mibefradil dihydrochloride - Drug Profile 108

Product Description 108

Mechanism Of Action 108

R&D Progress 108

nilotinib - Drug Profile 111

Product Description 111

Mechanism Of Action 111

R&D Progress 111

p28 - Drug Profile 117

Product Description 117

Mechanism Of Action 117

R&D Progress 117

paclitaxel trevatide - Drug Profile 119

Product Description 119

Mechanism Of Action 119

R&D Progress 119

palbociclib - Drug Profile 124

Product Description 124

Mechanism Of Action 124

R&D Progress 124

procarbazine hydrochloride - Drug Profile 137

Product Description 137

Mechanism Of Action 137

R&D Progress 137

TBX.OncV NSC - Drug Profile 138

Product Description 138

Mechanism Of Action 138

R&D Progress 138

TG-02 - Drug Profile 139

Product Description 139

Mechanism Of Action 139

R&D Progress 139

TOT-302 - Drug Profile 142

Product Description 142

Mechanism Of Action 142

R&D Progress 142

TVI-Brain-1 - Drug Profile 143

Product Description 143

Mechanism Of Action 143

R&D Progress 143

Anaplastic Astrocytoma - Dormant Projects 145

Anaplastic Astrocytoma - Discontinued Products 146

Anaplastic Astrocytoma - Product Development Milestones 147

Featured News & Press Releases 147

Sep 26, 2016: Orbus Therapeutics Announces Enrollment of First Patient in Phase 3 Trial in Late-Stage Brain Cancer 147

Dec 07, 2015: Burzynski Research Institute Announces Favorable Objective Response Rates and Overall Survival in Adults with Anaplastic Astrocytoma Following Antineoplastons A-10 and AS2-1 147

Jun 18, 2015: Burzynski Research Institute Announces Publication of Phase II Results in Adults with Recurrent Anaplastic Astrocytoma 148

Appendix 149

Methodology 149

Coverage 149

Secondary Research 149

Primary Research 149

Expert Panel Validation 149

Contact Us 149

Disclaimer 150

List of Tables

List of Tables

Number of Products under Development for Anaplastic Astrocytoma, H2 2017 9

Number of Products under Development by Companies, H2 2017 11

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 12

Number of Products under Development by Universities/Institutes, H2 2017 13

Products under Development by Companies, H2 2017 14

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15

Products under Development by Universities/Institutes, H2 2017 16

Number of Products by Stage and Target, H2 2017 18

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 19

Number of Products by Stage and Mechanism of Action, H2 2017 21

Number of Products by Stage and Route of Administration, H2 2017 23

Number of Products by Stage and Molecule Type, H2 2017 25

Anaplastic Astrocytoma – Pipeline by Advantagene Inc, H2 2017 26

Anaplastic Astrocytoma – Pipeline by Alfa Wassermann SpA, H2 2017 26

Anaplastic Astrocytoma – Pipeline by Amgen Inc, H2 2017 27

Anaplastic Astrocytoma – Pipeline by AngioChem Inc, H2 2017 27

Anaplastic Astrocytoma – Pipeline by Astellas Pharma Inc, H2 2017 28

Anaplastic Astrocytoma – Pipeline by Bayer AG, H2 2017 28

Anaplastic Astrocytoma – Pipeline by Boehringer Ingelheim GmbH, H2 2017 29

Anaplastic Astrocytoma – Pipeline by Burzynski Research Institute Inc, H2 2017 29

Anaplastic Astrocytoma – Pipeline by Cavion LLC, H2 2017 30

Anaplastic Astrocytoma – Pipeline by Celldex Therapeutics Inc, H2 2017 30

Anaplastic Astrocytoma – Pipeline by Merrimack Pharmaceuticals Inc, H2 2017 31

Anaplastic Astrocytoma – Pipeline by Millennium Pharmaceuticals Inc, H2 2017 32

Anaplastic Astrocytoma – Pipeline by Novartis AG, H2 2017 32

Anaplastic Astrocytoma – Pipeline by Orbus Therapeutics Inc, H2 2017 33

Anaplastic Astrocytoma – Pipeline by Pfizer Inc, H2 2017 33

Anaplastic Astrocytoma – Pipeline by Tocagen Inc, H2 2017 33

Anaplastic Astrocytoma – Pipeline by Tragara Pharmaceuticals Inc, H2 2017 34

Anaplastic Astrocytoma – Pipeline by TVAX Biomedical Inc, H2 2017 34

Anaplastic Astrocytoma – Pipeline by ZIOPHARM Oncology Inc, H2 2017 35

Anaplastic Astrocytoma – Dormant Projects, H2 2017 145

Anaplastic Astrocytoma – Discontinued Products, H2 2017 146

List of Figures

List of Figures

Number of Products under Development for Anaplastic Astrocytoma, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Number of Products under Development by Universities/Institutes, H2 2017 13

Number of Products by Top 10 Targets, H2 2017 17

Number of Products by Stage and Top 10 Targets, H2 2017 17

Number of Products by Top 10 Mechanism of Actions, H2 2017 20

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 20

Number of Products by Routes of Administration, H2 2017 22

Number of Products by Stage and Routes of Administration, H2 2017 22

Number of Products by Molecule Types, H2 2017 24

Number of Products by Stage and Molecule Types, H2 2017 24

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports